The risk of stroke in patients with atrial high-rate episodes (AHREs) depends on age, comorbidities and AHRE burden. Two randomized clinical trials on the use of oral anticoagulant therapy for stroke prevention in older patients with short and rare AHREs have reported conflicting findings on the efficacy of oral anticoagulation in this patient population, although both trials report a significantly increased risk of major bleeding with oral anticoagulation.
This is a preview of subscription content, log in via an institution to check access.
References
Hindricks, G. et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 42, 373–498 (2021).
Ruff, C. T. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383, 955–962 (2014).
Freedman, B. et al. Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat. Rev. Cardiol. 14, 701–714 (2017).
Lip, G. Y. H. et al. Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal. Europace 25, euad226 (2023).
Vitolo, M. et al. Device-detected atrial high rate episodes and the risk of stroke/thrombo-embolism and atrial fibrillation incidence: a systematic review and meta-analysis. Eur. J. Intern. Med. 92, 100–106 (2021).
Healey, J. S. et al. Subclinical atrial fibrillation and the risk of stroke. N. Engl. J. Med. 366, 120–129 (2012).
Singer, D. E., Ziegler, P. D., Koehler, J. L., Sarkar, S. & Passman, R. S. Temporal association between episodes of atrial fibrillation and risk of ischemic stroke. JAMA Cardiol. 6, 1364–1369 (2021).
Kirchhof, P. et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes. N. Engl. J. Med. 389, 1167–1179 (2023).
Healey, J. S. et al. Apixaban for stroke prevention in subclinical atrial fibrillation. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2310234 (2023).
Van Gelder, I. C. et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur. Heart J. 38, 1339–1344 (2017).
Becher, N. et al. Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 hours. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehad771 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Potpara, T., Blomstrom-Lundqvist, C. Anticoagulation in patients with atrial high-rate episodes. Nat Rev Cardiol 21, 5–6 (2024). https://doi.org/10.1038/s41569-023-00963-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-023-00963-2
- Springer Nature Limited